Trial Profile
Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on county-wide invasive pneumococcal disease (IPD) in Pediatric population
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2018
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- 19 Nov 2018 New trial record
- 07 Oct 2018 Results presented at the IDWeek 2018